echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Science sub-journal cover: lysovirus and CAR-T cells work together to eradicate solid tumors.

    Science sub-journal cover: lysovirus and CAR-T cells work together to eradicate solid tumors.

    • Last Update: 2020-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Our study shows that lysovirus is a powerful way to target solid tumors more effectively in combination with CAR-T cell therapy.
    Saul Priceman, one of the authors of the study, said: "This treatment platform addresses two major challenges that make it difficult to treat solid tumors with immunotherapy.
    , on solid tumors, there are limited targets suitable for T-cells with CAR redirection.
    second, solid tumors are surrounded by the micro-environment of so-called immunosuppressive tumors, which do not work effectively when a CAR-T cell tries to enter the tumor, survive and kill the cancer cells.
    lysolysed tumor virus can break through this barrier.
    " study is also used as a cover story for Science Translational Medicine (Photo: Science Translational Medicine; Credit: A. K. PARK, S.I. KIM, S. J. PRICEMAN/City of Hope In this preclinical study, scientists cleverly equipped CAR-T cells with "drivers" for entering solid tumors using lysovirus.
    genetically engineered a tumor-soluble virus to enter tumor cells, forcing them to express a cut-off CD19 (CD19t) on the surface.
    trials have shown that the lysolytic virus, known as OV19t, can work in triple-negative breast cancer cell lineages as well as in pancreatic, prostate, ovarian and head and neck cancer, and brain tumor cells.
    -modified lysovirus allows tumor cells to express CD19 (purple) on the surface (Photo: Source: Reference 2; Credit: City of Hope) After tumor cells infected with OV19t, scientists used CAR-T cells specifically targeted at CD19 to identify and attack these solid tumors.
    tests conducted in in-body experiments and various mouse tumor models showed that CD19t was expressed in tumor cells much faster than viruses killed them, creating a time window for CAR-T cells targeting CD19.
    cells that are killed by the virus release additional copies of the virus and transmit them to neighboring tumor cells, making them targets for CAR-T cells.
    , the combination of lysovirus and CAR-T cells creates a powerful synergistic effect.
    , after using this combination therapy to eradicate solid tumors, mice showed long-term protective anti-tumor immunity, and the immune system established a memory response to tumors.
    this result means that this combined treatment will help prevent recurrence.
    researchers say they are now designing clinical trials to test the combination in patients.
    of course they will first test the safety of OV19t in solid tumor patients.
    if it is proven to be safe and effective, then lysovirus and CAR-T cell therapy can be tested in turn.
    is expected to begin in 2022.
    resources: s1? Scientists use two powerful to todd solid tumors, Retrived September 3, 2020, from s2, Park et al., 2020, ScienceAl Medicine. Effective group immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors, DOI: 10.1126/scitranslmed.aaz1863.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.